Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma

by Kyu Seo Kim, Rishi R. Sekar, Dattatraya Patil, Michelle A. Dimarco, Haydn T. Kissick, Mehmet A. Bilen, Adeboye O. Osunkoya, Viraj A. Master
Published 2018-04-01

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer

by Huifang Lv, Junling Zhang, Keran Sun, Caiyun Nie, Beibei Chen, Jianzheng Wang, Weifeng Xu, Saiqi Wang, Yingjun Liu, Xiaobing Chen
Published 2021-02-01

Programmed cell death protein-1 (PD-1) protects liver damage by suppressing IFN-γ expression in T cells in infants and neonatal mice

by Xuangjie Guo, Yiping Xu, Wei Luo, Rongli Fang, Li Cai, Ping Wang, Yuxia Zhang, Zhe Wen, Yanhui Xu
Published 2021-07-01

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

by Aikaterini Tsiogka, Johann W. Bauer, Aikaterini Patsatsi
Published 2021-01-01

Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced...

by Mei Zhao MM, Yiruo Zhang MM, Hua Wang MD, PhD, Pingping Liu MD, Jie Da MD, Yingying Du MD
Published 2021-09-01

Corrigendum: Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer

by Huifang Lv, Junling Zhang, Keran Sun, Caiyun Nie, Beibei Chen, Jianzheng Wang, Weifeng Xu, Saiqi Wang, Yingjun Liu, Xiaobing Chen
Published 2021-04-01

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

by Biagio Ricciuti, MD, Abdul Rafeh Naqash, MD, Jarushka Naidoo, MD, Kartik Sehgal, MD, Adam Miller, MD, Kenneth Kehl, MD, MPH, Deepti Venkatraman, MPH, Jacob Sands, MD, Giuseppe Lamberti, MD, Gonzalo Recondo, MD, PhD, Jiajia Zhang, MD, Shravanti Macherla, MD, Sameer Baig, MD, Paul Walker, MD, Deepa Rangachari, MD, Justin F. Gainor, MD, Daniel B. Costa, MD, Naiyer Rizvi, MD, Lynette M. Sholl, MD, Mizuki Nishino, MD, MPH, Brian Henick, MD, Anna F. Farago, MD, PhD, Mark M. Awad, MD, PhD
Published 2020-11-01

Human IgA-Expressing Bone Marrow Plasma Cells Characteristically Upregulate Programmed Cell Death Protein-1 Upon B Cell Receptor Stimulation

by Annika Wiedemann, Annika Wiedemann, Marie Lettau, Marie Lettau, Ina Wirries, Ina Wirries, Annemarie Jungmann, Abdulrahman Salhab, Gilles Gasparoni, Henrik E. Mei, Carsten Perka, Jörn Walter, Andreas Radbruch, Andreia C. Lino, Andreia C. Lino, Thomas Dörner, Thomas Dörner
Published 2021-02-01

Human CD8+CD28− T Suppressor Cells Expanded by IL-15 In Vitro Suppress in an Allospecific and Programmed Cell Death Protein 1-Dependent Manner

by Fu Feng, Yanjun Liu, Guihuan Liu, Ping Zhu, Manman Zhu, Hua Zhang, Xiao Lu, Jiumin Liu, Xunrong Luo, Yuming Yu
Published 2018-06-01

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1...

by Maysaloun Merhi, Maysaloun Merhi, Afsheen Raza, Afsheen Raza, Varghese Philipose Inchakalody, Varghese Philipose Inchakalody, Abdulqadir Jeprel Japer Nashwan, Abdulqadir Jeprel Japer Nashwan, Niloofar Allahverdi, Niloofar Allahverdi, Roopesh Krishnankutty, Shahab Uddin, Abdul Rehman Zar Gul, Mohammed Ussama Al Homsi, Said Dermime, Said Dermime
Published 2018-07-01

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer

by Xin Yan, Xin Yan, Yongtian Zhao, Yang Liu, Qingming Yang, Liang Dong, Zhiqiang Wu, Jing Nie, Deyun Chen, Miaomiao Bai, Dongdong Ti, Kaichao Feng, Weidong Han, Weidong Han
Published 2020-10-01

Role of microRNA 4717, its effects on programmed cell death protein-1 in hepatitis B infection, and interaction between PDCD1 and miR-4717

by Junhua Li, Andong Li
Published 2020-06-01

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer

by Shahla Bari, Austin Chan, Sanjay R. Jain, Christopher J. Hostler
Published 2019-01-01

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation

by Ieva Saulite, Desislava Ignatova, Yun-Tsan Chang, Christina Fassnacht, Florentia Dimitriou, Eleni Varypataki, Florian Anzengruber, Mirjam Nägeli, Antonio Cozzio, Reinhard Dummer, Julia Scarisbrick, Steve Pascolo, Wolfram Hoetzenecker, Malgorzata Bobrowicz, Emmanuella Guenova
Published 2020-01-01

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

by Lin Zhang, Wuqian Mai, Wuqian Mai, Wenyang Jiang, Qing Geng
Published 2020-11-01

Tumor Size Matters—Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy

by Jean Philippe Nesseler, Mi-Heon Lee, Christine Nguyen, Anusha Kalbasi, James W. Sayre, Tahmineh Romero, Philippe Nickers, William H. McBride, Dörthe Schaue
Published 2020-03-01

Eosinophilic fasciitis in association with nivolumab: The importance of eosinophilia

by Gabriela Pabón-Cartagena, MD, Andrea López, BS, Erika Watts, MD, Norma Alonso, MD
Published 2020-12-01

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies

by Xuan Wang, Qing Ji, Xieqiao Yan, Bin Lian, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Siming Li, Li Zhou, Chuanliang Cui, Jun Guo
Published 2020-09-01

Immune-Checkpoint Blockade Therapy in Lymphoma

by Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami
Published 2020-07-01

Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid

by Xiaoyan Zhang, Dongjiang Sui, Dong Wang, Lina Zhang, Ruiyan Wang
Published 2021-09-01